Indian J Pharm Close
 

Table 3: Question 1 (ii): What fraction of your patients with HR +ve/Her2 −ve breast cancer in the first‑line metastatic setting have visceral involvement?

Table 3: Question 1 (ii): What fraction of your patients with HR +ve/Her2 −ve breast cancer in the first‑line metastatic setting have visceral involvement?